Lupus nephritis biomarkers

Clinical Immunology

Volumn 185, Issue , 2017, Pages 10-20

  Soliman, Samar ^a,b   Mohan, Chandra ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b Minia University   (Egypt)

Author keywords

Adhesion molecules; Biomarkers; Chemokines; Cytokines; Diagnostics; Proteomics

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; GROWTH FACTOR; MICRORNA; PROTEOME;

ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; PROTEOMICS; URINE LEVEL; URINE SEDIMENT; ANIMAL; BLOOD; URINE;

ANIMALS; BIOMARKERS; HUMANS; LUPUS NEPHRITIS;

EID: 84981718803     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.08.001     Document Type: Article

References (191)

1. Yap, D.Y., Lai, K.N., Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J. Biomed. Biotechnol., 2010, 2010, 365083.
2. Mok, C.C., Biomarkers for lupus nephritis: a critical appraisal. J. Biomed. Biotechnol., 2010, 2010, 638413.
3. Abujam, B., Cheekatla, S., Aggarwal, A., Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. Lupus 22:6 (May 2013), 614–623.
4. Dooley, M.A., Hogan, S., Jennette, C., Falk, R., Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular disease collaborative network. Kidney Int. 51:4 (Apr 1997), 1188–1195.
5. Mok, C.C., Therapeutic options for resistant lupus nephritis. Semin. Arthritis Rheum. 36:2 (Oct 2006), 71–81.
6. Faurschou, M., Starklint, H., Halberg, P., Jacobsen, S., Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J. Rheumatol. 33:8 (Aug 2006), 1563–1569.
7. Szeto, C.C., Urine miRNA in nephrotic syndrome. Clin. Chim. Acta 436 (Sep 25 2014), 308–313.
8. Hanaoka, M., Gono, T., Kawaguchi, Y., Uchida, K., Koseki, Y., Katsumata, Y., Kaneko, H., Takagi, K., Ichida, H., Nitta, K., Yamanaka, H., Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis. Rheumatology (Oxford) 52:12 (Dec 2013), 2149–2157.
9. Linnik, M.D., Hu, J.Z., Heilbrunn, K.R., Strand, V., Hurley, F.L., Joh, T., LJP 394 investigator consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 52:4 (Apr 2005), 1129–1137.
10. Mannik, M., Merrill, C.E., Stamps, L.D., Wener, M.H., Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J. Rheumatol. 30 (2003), 1495–1504.
11. Bijl, M., Horst, G., Bootsma, H., Limburg, P.C., Kallenberg, C.G., Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann. Rheum. Dis. 62 (2003), 534–539.
12. Bootsma, H., Spronk, P., Derksen, R., de Boer, G., Wolters-Dicke, H., Hermans, J., et al. Prevention of relapses in systemic lupus erythematosus. Lancet 345 (1995), 1595–1599.
13. Ho, A., Magder, L.S., Barr, S.G., Petri, M., Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 44 (2001), 2342–2349.
14. Gladman, D.D., Hirani, N., Ibanez, D., Urowitz, M.B., Clinically active serologically quiescent systemic lupus erythematosus. J. Rheumatol. 30 (2003), 1960–1962.
15. Barr, R.G., Seliger, S., Appel, G.B., Zuniga, R., D'Agati, V., Salmon, J., et al. Prognosis in proliferative lupus nephritis: the role of socioeconomic status and race/ethnicity. Nephrol. Dial. Transplant. 18 (2003), 2039–2046.
16. Binder, E., Edelbauer, M., Use of biomarkers in the management of children with lupus. Curr. Rheumatol. Rep., 15(3), Mar 2013, 312.
17. Watson, L., Beresford, M.W., Urine biomarkers in juvenile-onset SLE nephritis. Pediatr. Nephrol. 28:3 (Mar 2013), 363–374.
18. Porcel, J.M., Ordo, J., Castro-Salomo, A., et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin. Immunol. Immunopathol. 74 (1995), 2883–2888.
19. Welch, T.R., Blystone, L.W., Renal disease associated with inherited disorders of the complement system. Pediatr. Nephrol. 24:8 (2009), 149–1444.
20. Moroni, G., Quaglini, S., Radice, A., Trezzi, B., Raffiotta, F., Messa, P., Sinico, R.A., The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J. Immunol. Res., 2015, 2015, 106904.
21. Ayodele, O.E., Okpechi, I.G., Swanepoel, C.R., Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology 15:4 (2010), 482–490.
22. Rovin, B.H., Birmingham, D.J., Nagaraja, H.N., Yu, C.Y., Hebert, L.A., Biomarker discovery in human SLE nephritis. Bull. NYU Hosp. Jt. Dis. 65:3 (2007), 187–193.
23. Li, Y., Tucci, M., Narain, S., Barnes, E.V., Sobel, E.S., Segal, M.S., Richards, H.B., Urinary biomarkers in lupus nephritis. Autoimmun. Rev. 5:6 (Jul 2006), 383–388.
24. Rovin, B.H., Song, H., Birmingham, D.J., et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16:12 (Dec 2005), 467–473.
25. Illei, G.G., Tackey, E., Lapteva, L., et al. Biomarkers in systemic lupus erythematosus: general overview of biomarkers and their applicability. Arthritis Rheum. 50:6 (Jun 2004), 1709–1720.
26. Richards, H.B., Satoh, M., Shaw, M., Libert, C., Poli, V., Reeves, W.H., Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 188:5 (Sep 7 1998), 985–990.
27. Linker-Israeli, M., Deans, R.J., Wallace, D.J., Prehn, J., Ozeri-Chen, T., Klinenberg, J.R., Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 147:1 (Jul 1 1991), 117–123.
28. Garaud, S., Le Dantec, C., Jousse-Joulin, S., Hanrotel-Saliou, C., Saraux, A., Mageed, R.A., Youinou, P., Renaudineau, Y., IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J. Immunol. 182:9 (May 1 2009), 5623–5632.
29. Iwano, M., Dohi, K., Hirata, E., Kurumatani, N., Horii, Y., Shiiki, H., Fukatsu, A., Matsuda, T., Hirano, T., Kishimoto, T., et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin. Nephrol. 40:1 (Jul 1993), 16–21.
30. Horwitz, D.A., Gray, J.D., Behrendsen, S.C., et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 41 (1998), 838–844.
31. Gröndal, G., Gunnarsson, I., Rönnelid, J., et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 18 (2000), 565–570.
32. Susianti, H., Iriane, V.M., Dharmanata, S., Handono, K., Widijanti, A., Gunawan, A., Kalim, H., Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology 22:1 (Mar 2015), 65–71.
33. Nalbandian, A., Crispín, J.C., Tsokos, G.C., Interleukin-17 and systemic lupus erythematosus: current concepts. Clin. Exp. Immunol. 157:2 (Aug 2009), 209–215.
34. Alunno, A., Bartoloni, E., Bistoni, O., Nocentini, G., Ronchetti, S., Caterbi, S., Valentini, V., Riccardi, C., Gerli, R., Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin. Dev. Immunol., 2012, 2012, 823085.
35. Schwartz, N., Su, L., Burkly, L.C., Mackay, M., Aranow, C., Kollaros, M., Michaelson, J.S., Rovin, B., Putterman, C., Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 27:4 (Dec 2006), 242–250.
36. Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem., 272, 1997, 32401e10.
37. Wiley, S.R., Winkles, J.A., TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev., 14, 2003, 241e9.
38. Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity, 15, 2001, 837e46.
39. Chicheportiche, Y., Chicheportiche, R., Sizing, I., Thompson, J., Benjamin, C.B., Ambrose, C., et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res., 4, 2002, 126e33.
40. Adhya, Z., Borozdenkova, S., Karim, M.Y., The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrol. Dial. Transplant. 26:10 (Oct 2011), 3273–3280.
41. Schwartz, N., Rubinstein, T., Burkly, L.C., Collins, C.E., Blanco, I., Su, L., Hojaili, B., Mackay, M., Aranow, C., Stohl, W., Rovin, B.H., Michaelson, J.S., Putterman, C., Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res. Ther., 11(5), 2009, R143.
42. Tucci, M., Barnes, E.V., Sobel, E.S., Croker, B.P., Segal, M.S., Reeves, W.H., Richards, H.B., Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 50:6 (Jun 2004), 1842–1849.
43. Tian, S., Li, J., Wang, L., Liu, T., Liu, H., Cheng, G., Liu, D., Deng, Y., Gou, R., Wan, Y., Jia, J., Chen, C., Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm. Res. 56:7 (Jul 2007), 304–310.
44. Aten, J., Roos, A., Claessen, N., Schilder-Tol, E.J., Ten Berge, I.J., Weening, J.J., Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J. Am. Soc. Nephrol. 11:8 (Aug 2000), 1426–1438.
45. Wu, T., Xie, C., Wang, H.W., Zhou, X.J., Schwartz, N., Calixto, S., Mackay, M., Aranow, C., Putterman, C., Mohan, C., Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 179:10 (Nov 15 2007), 7166–7175.
46. Rovin, B.H., Song, H., Hebert, L.A., Nadasdy, T., Nadasdy, G., Birmingham, D.J., Yung Yu, C., Nagaraja, H.N., Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int. 68:4 (Oct 2005), 1825–1833.
47. Wulster-Radcliffe, M.C., Ajuwon, K.M., Wang, J., Christian, J.A., Spurlock, M.E., Adiponectin differentially regulates cytokines in porcine macrophages. Biochem. Biophys. Res. Commun. 316:3 (Apr 9 2004), 924–929.
48. Kawanami, D., Maemura, K., Takeda, N., Harada, T., Nojiri, T., Imai, Y., Manabe, I., Utsunomiya, K., Nagai, R., Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem. Biophys. Res. Commun. 314:2 (Feb 6 2004), 415–419.
49. Chen, T.H., Chen, L., Hsieh, M.S., Chang, C.P., Chou, D.T., Tsai, S.H., Evidence for a protective role for adiponectin in osteoarthritis. Biochim. Biophys. Acta 1762:8 (Aug 2006), 711–718.
50. Neumeier, M., Weigert, J., Schäffler, A., Wehrwein, G., Müller-Ladner, U., Schölmerich, J., Wrede, C., Buechler, C., Different effects of adiponectin isoforms in human monocytic cells. J. Leukoc. Biol. 79:4 (Apr 2006), 803–808.
51. Rovin, B.H., Song, H., Chemokine induction by the adipocyte-derived cytokine adiponectin. Clin. Immunol. 120:1 (Jul 2006), 99–105.
52. Tesch, G.H., Maifert, S., Schwarting, A., Rollins, B.J., Kelley, V.R., Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas (lpr) mice. J. Exp. Med. 190:12 (Dec 20 1999), 1813–1824.
53. Hasegawa, H., Kohno, M., Sasaki, M., Inoue, A., Ito, M.R., Terada, M., Hieshima, K., Maruyama, H., Miyazaki, J., Yoshie, O., Nose, M., Fujita, S., Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum. 48:9 (Sep 2003), 2555–2566.
54. Shimizu, S., Nakashima, H., Masutani, K., Inoue, Y., Miyake, K., Akahoshi, M., Tanaka, Y., Egashira, K., Hirakata, H., Otsuka, T., Harada, M., Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 43:9 (Sep 2004), 1121–1128.
55. Rovin, B.H., Rumancik, M., Tan, L., Dickerson, J., Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab. Investig. 71:4 (Oct 1994), 536–542.
56. Wada, T., Yokoyama, H., Su, S.B., Mukaida, N., Iwano, M., Dohi, K., Takahashi, Y., Sasaki, T., Furuichi, K., Segawa, C., Hisada, Y., Ohta, S., Takasawa, K., Kobayashi, K., Matsushima, K., Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int. 49:3 (Mar 1996), 761–767.
57. Tsai, C.Y., Wu, T.H., Yu, C.L., Lu, J.Y., Tsai, Y.Y., Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85:3 (Jul 2000), 207–214.
58. Chan, R.W., Lai, F.M., Li, E.K., Tam, L.S., Wong, T.Y., Szeto, C.Y., Li, P.K., Szeto, C.C., Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 50:9 (Sep 2004), 2882–2890.
59. Rovin, B.H., Doe, N., Tan, L.C., Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am. J. Kidney Dis. 27:5 (May 1996), 640–646.
60. Kiani, A.N., Johnson, K., Chen, C., Diehl, E., Hu, H., Vasudevan, G., Singh, S., Magder, L.S., Knechtle, S.J., Petri, M., Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J. Rheumatol. 36:10 (Oct 2009), 2224–2230.
61. Rovin, B.H., Song, H., Birmingham, D.J., Hebert, L.A., Yu, C.Y., Nagaraja, H.N., Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16:2 (Feb 2005), 467–473.
62. Mirfeizi, Z., Mahmoudi, M., Naghibi, M., Hatef, M., Sharifipour, F., Jokar, M., Zeraati, A., Shariati Sarabi, Z., Azarian, A., Urine monocyte chemoattractant protein-1(UMCP-1) as a biomarker of renal involvement in systemic lupus erythematosus. Iran J. Basic Med. Sci. 15:6 (Nov 2012), 1191–1195.
63. Torabinejad, S., Mardani, R., Habibagahi, Z., Roozbeh, J., Khajedehi, P., Pakfetrat, M., Banihashemi, M.A., Banihashemi, S.J., Urinary monocyte chemotactic protein-1 and transforming growth factor-β in systemic lupus erythematosus. Ind. J. Nephrol. 22:1 (Jan 2012), 5–12.
64. Marks, S.D., Shah, V., Pilkington, C., Tullus, K., Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr. Nephrol. 25:11 (Nov 2010), 2283–2288.
65. Wada, T., Yokoyama, H., Tomosugi, N., Hisada, Y., Ohta, S., Naito, T., Kobayashi, K., Mukaida, N., Matsushima, K., Detection of urinary interleukin-8 in glomerular diseases. Kidney Int. 46:2 (Aug 1994), 455–460.
66. Neville, L.F., Mathiak, G., Bagasra, O., The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 8:3 (Sep 1997), 207–219.
67. Enghard, P., Humrich, J.Y., Rudolph, B., Rosenberger, S., Biesen, R., Kuhn, A., Manz, R., Hiepe, F., Radbruch, A., Burmester, G.R., Riemekasten, G., CXCR3 + CD4 + T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum. 60:1 (Jan 2009), 199–206.
68. Avihingsanon, Y., Phumesin, P., Benjachat, T., Akkasilpa, S., Kittikowit, V., Praditpornsilpa, K., Wongpiyabavorn, J., Eiam-Ong, S., Hemachudha, T., Tungsanga, K., Hirankarn, N., Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int. 69:4 (Feb 2006), 747–753.
69. Eriksson, C., Eneslätt, K., Ivanoff, J., Rantapää-Dahlqvist, S., Sundqvist, K.G., Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 12:10 (2003), 766–774.
70. Narumi, S., Takeuchi, T., Kobayashi, Y., Konishi, K., Serum levels of IFN-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine 12:10 (Oct 2000), 1561–1565.
71. Romagnani, P., Lazzeri, E., Lasagni, L., Mavilia, C., Beltrame, C., Francalanci, M., Rotondi, M., Annunziato, F., Maurenzig, L., Cosmi, L., Galli, G., Salvadori, M., Maggi, E., Serio, M., IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J. Am. Soc. Nephrol. 13:1 (Jan 2002), 53–64.
72. Reyes-Thomas, J., Blanco, I., Putterman, C., Urinary biomarkers in lupus nephritis. Clin. Rev. Allergy Immunol. 40:3 (Jun 2011), 138–150.
73. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16.
74. Shimaoka, T., Nakayama, T., Fukumoto, N., Kume, N., Takahashi, S., Yamaguchi, J., Minami, M., Hayashida, K., Kita, T., Ohsumi, J., Yoshie, O., Yonehara, S., Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J. Leukoc. Biol. 75:2 (Feb 2004), 267–274.
75. Chandrasekar, B., Bysani, S., Mummidi, S., CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J. Biol. Chem. 279:5 (Jan 30 2004), 3188–3196.
76. Shimaoka, T., Nakayama, T., Kume, N., Takahashi, S., Yamaguchi, J., Minami, M., Hayashida, K., Kita, T., Ohsumi, J., Yoshie, O., Yonehara, S., Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J. Immunol. 171:4 (Aug 15 2003), 1647–1651.
77. Chan, R.W., Lai, F.M., Li, E.K., Tam, L.S., Chow, K.M., Li, P.K., Szeto, C.C., Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis. Nephrol. (Carlton) 11:3 (Jun 2006), 219–225.
78. Taub, D.D., Oppenheim, J.J., Chemokines, inflammation and the immune system. Ther. Immunol. 1:4 (Aug 1994), 229–246.
79. Kaneko, H., Ogasawara, H., Naito, T., Akimoto, H., Lee, S., Hishikawa, T., Sekigawa, I., Tokano, Y., Takasaki, Y., Hirose, S.I., Hashimoto, H., Circulating levels of beta-chemokines in systemic lupus erythematosus. J. Rheumatol. 26:3 (Mar 1999), 568–573.
80. Robak, E., Woźniacka, A., Sysa-Jedrzejowska, A., Stepień, H., Robak, T., Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur. Cytokine Netw. 12:3 (Jul-Sep 2001), 445–452.
81. Landolt-Marticorena, C., Morrison, S., Reich, H., et al. Clinical utility of changes in cyto/chemokines as markers of disease activity in systemic lupus erythematosus [abstract]. Arthritis Rheum., 60(Suppl. 10), 2009, 922.
82. Guan, J., Wang, G., Tam, L.S., Kwan, B.C., Li, E.K., Chow, K.M., Li, P.K., Szeto, C.C., Urinary sediment ICAM-1 level in lupus nephritis. Lupus 21:11 (Oct 2012), 1190–1195.
83. Daniel, L., Sichez, H., Giorgi, R., Dussol, B., Figarella-Branger, D., Pellissier, J.F., Berland, Y., Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int. 60:6 (Dec 2001), 2215–2221.
84. Wuthrich, R.P., Jevnikar, A.M., Takei, F., Glimcher, L.H., Kelley, V.E., Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. Am. J. Pathol. 136:2 (Feb 1990), 441–450.
85. Pallis, M., Robson, D.K., Haskard, D.O., Powell, R.J., Distribution of cell adhesion molecules in skeletal muscle from patients with systemic lupus erythematosus. Ann. Rheum. Dis. 52:9 (Sep 1993), 667–671.
86. Belmont, H.M., Buyon, J., Giorno, R., Abramson, S., Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum. 37:3 (Mar 1994), 376–383.
87. Lhotta, K., Neumayer, H.P., Joannidis, M., Geissler, D., König, P., Renal expression of intercellular adhesion molecule-1 in different forms of glomerulonephritis. Clin. Sci. (Lond.) 81:4 (Oct 1991), 477–481.
88. Frank, P.G., Lisanti, M.P., ICAM-1: role in inflammation and in the regulation of vascular permeability. Am. J. Physiol. Heart Circ. Physiol. 295:3 (Sep 2008), H926–H927.
89. Grande, J.P., Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 7:9 (1998), 604–610.
90. Pérez de Lema, G., Maier, H., Nieto, E., Vielhauer, V., Luckow, B., Mampaso, F., Schlöndorff, D., Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J. Am. Soc. Nephrol. 12:7 (Jul 2001), 1369–1382.
91. Kitamura, S., Maeshima, Y., Sugaya, T., Sugiyama, H., Yamasaki, Y., Makino, H., Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp. Nephrol. 95:2 (2003), e79–e86.
92. Schrijvers, B.F., Flyvbjerg, A., De Vriese, A.S., The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 65:6 (Jun 2004), 2003–2017.
93. Chan, R.W., Lai, F.M., Li, E.K., Tam, L.S., Chow, K.M., Lai, K.B., Li, P.K., Szeto, C.C., Intrarenal cytokine gene expression in lupus nephritis. Ann. Rheum. Dis. 66:7 (Jul 2007), 886–892.
94. Hammad, A.M., Youssef, H.M., El-Arman, M.M., Transforming growth factor beta 1 in children with systemic lupus erythematosus: a possible relation with clinical presentation of lupus nephritis. Lupus 15:9 (2006), 608–612.
95. Wang, G., Tam, L.S., Li, E.K., Kwan, B.C., Chow, K.M., Luk, C.C., Li, P.K., Szeto, C.C., Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 20:5 (Apr 2011), 493–500.
96. Chafin, C.B., Regna, N.L., Hammond, S.E., Reilly, C.M., Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int. Immunopharmacol. 17:3 (Nov 2013), 894–906.
97. Rubinstein, T., Pitashny, M., Putterman, C., The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/lipocalin-2 as a biomarker for lupus nephritis. Autoimmun. Rev. 7:3 (Jan 2008), 229–234.
98. Tong, Z., Wu, X., Ovcharenko, D., Zhu, J., Chen, C.S., Kehrer, J.P., Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem. J. 391:Pt 2 (Oct 15 2005), 441–448.
99. Brunner, H.I., Mueller, M., Rutherford, C., Passo, M.H., Witte, D., Grom, A., Mishra, J., Devarajan, P., Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 54:8 (Aug 2006), 2577–2584.
100. Devireddy, L.R., Gazin, C., Zhu, X., Green, M.R., A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123:7 (Dec 29 2005), 1293–1305.
101. Suzuki, M., Wiers, K.M., Klein-Gitelman, M.S., Haines, K.A., Olson, J., Onel, K.B., O'Neil, K., Passo, M.H., Singer, N.G., Tucker, L., Ying, J., Devarajan, P., Brunner, H.I., Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr. Nephrol. 23:3 (Mar 2008), 403–412.
102. Kiani, A., Arthur, J., Magder, L., et al. Lupus nephritis: urinary biomarkers [abstract]. Arthritis Rheum., 60(Suppl. 10), 2009, 917.
103. Kiani, A., Mohan, C., Wu, T., et al. VCAM-1 is a better measure of SLE renal activity than NGAL and CXCL16 [abstract]. Arthritis Rheum., 60(Suppl. 10), 2009, 919.
104. Pitashny, M., Schwartz, N., Qing, X., Hojaili, B., Aranow, C., Mackay, M., Putterman, C., Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 56:6 (Jun 2007), 1894–1903.
105. Landolt-Marticorena, C., Reich, H., Morrison, S., et al. Urine cyto/ chemokines correlate with renal histopathology in systemic lupus erythematosus [abstract]. Arthritis Rheum., 60(Suppl. 10), 2009, 564.
106. Torres-Salido, M., Cortes-Hernandez, J., Urquizu-Padilla, M., et al. Neutrophil gelatinase-associated lipocalin (Ngal) as a urinary biomarker of disease activity and severity in lupus nephritis [abstract]. Arthritis Rheum., 60(Suppl. 10), 2009, 927.
107. Hinze, C.H., Suzuki, M., Klein-Gitelman, M., Passo, M.H., Olson, J., Singer, N.G., Haines, K.A., Onel, K., O'Neil, K., Silverman, E.D., Tucker, L., Ying, J., Devarajan, P., Brunner, H.I., Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 60:9 (Sep 2009), 2772–2781.
108. Rubinstein, T., Pitashny, M., Levine, B., Schwartz, N., Schwartzman, J., Weinstein, E., Pego-Reigosa, J.M., Lu, T.Y., Isenberg, D., Rahman, A., Putterman, C., Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 49:5 (May 2010), 960–971.
109. Abdallah, E., El-Shishtawy, S., Sherif, N., Abdelwahab, M.A., Diagnostic performance of urinary osteoprotegrin as a novel biomarker for early detection of lupus nephritis activity. Life Sci. J. 12:1 (2015), 75–81.
110. Simonet, W.S., Lacey, D.L., Dunstan, C.R., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997), 309–319.
111. Yun, T.J., Chaudhary, P.M., GL, S., OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161 (1998), 6113–6121.
112. Hofbauer, L.C., Khosla, S., Dunstan, C.R., The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15 (2000), 2–12.
113. Adnan, N., Kiani, K., Johnson, C.C., Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J. Rheumatol. 36 (2009), 10–17.
114. Nozaki, Y., Kinoshita, K., Yano, T., Shiga, T., Hino, S., Niki, K., Kishimoto, K., Funauchi, M., Matsumura, I., Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis. Lupus 23:8 (Jul 2014), 769–777.
115. Ichimura, T., Bonventre, J.V., Bailly, V., Wei, H., Hession, C.A., Cate, R.L., Sanicola, M., Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273:7 (Feb 13 1998), 4135–4142.
116. Han, W.K., Alinani, A., Wu, C.L., Michaelson, D., Loda, M., McGovern, F.J., Thadhani, R., Bonventre, J.V., Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J. Am. Soc. Nephrol. 16:4 (Apr 2005), 1126–1134.
117. Kuehn, E.W., Park, K.M., Somlo, S., Bonventre, J.V., Kidney injury molecule-1 expression in murine polycystic kidney disease. Am. J. Physiol. Ren. Physiol. 283 (2002), 1326–1336.
118. Han, W.K., Bailly, V., Abichandani, R., Thadhani, R., Kidney injury molecule-1 (Kim-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62 (2002), 237–244.
119. Hutchison, C.A., Basnayake, K., Cockwell, P., Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat. Rev. Nephrol 5 (2009), 621–628.
120. Aggarwal, R., SequeiraW, Kokebie R. et al., Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res. 63 (2011), 891–898.
121. Hopper, J.E., Golbus, J., Meyer, C. et al., Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J. Clin. Immunol 20 (2000), 123–137.
122. Yokoyama, H., Wada, T., Hara, A. et al., The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 66 (2004), 2382–2388.
123. Watson, L., Midgley, A., Pilkington, C., Tullus, K., Marks, S., Holt, R., Jones, C., Beresford, M., Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 21:5 (Apr 2012), 496–501.
124. Suzuki, M., Wiers, K., Brooks, E.B., et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr. Res. 65 (2009), 530–536.
125. Erdener, D., Aksu, K., Biçer, I., Doğanavşargil, E., Kutay, F.Z., Urinary N-acetyl-beta-D-glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis. J. Clin. Lab. Anal. 19:4 (2005), 172–176.
126. Price, R.G., The role of NAG (N-acetyl-b-D-glucosaminidase) in the diagnosis of kidney disease, including the monitoring of nephrotoxicity. Clin. Nephrol. 38 (1992), 14–19.
127. Ganz, T., Nemeth, E., Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823:9 (Sep 2012), 1434–1443.
128. Zhang, X., Nagaraja, H.N., Nadasdy, T., Song, H., McKinley, A., Prosek, J., Kamadana, S., Rovin, B.H., A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int. 81:4 (Feb 2012), 401–406.
129. Wu, T., Du, Y., Han, J., Singh, S., Xie, C., Guo, Y., Zhou, X.J., Ahn, C., Saxena, R., Mohan, C., Urinary angiostatin–a novel putative marker of renal pathology chronicity in lupus nephritis. Mol. Cell. Proteomics 12:5 (May 2013), 1170–1179.
130. Somparn, P., Hirankarn, N., Leelahavanichkul, A., Khovidhunkit, W., Thongboonkerd, V., Avihingsanon, Y., Urinary proteomics revealed prostaglandin H2D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis. J. Proteome 75 (2012), 3240–3247.
131. Simón, J.A., Cabiedes, J., Ortiz, E., Alcocer-Varela, J., Sánchez-Guerrero, J., Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology (Oxford) 43:2 (Feb 2004), 220–224.
132. Mohan, C., Adams, S., Stanik, V., Datta, S.K., Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177:5 (May 1 1993), 1367–1381.
133. Amoura, Z., Koutouzov, S., Piette, J.C., The key role of nucleosomes in lupus. Curr. Opin. Rheumatol. 12 (2000), 369–373.
134. Gómez-Puerta, J.A., Burlingame, R.W., Cervera, R., Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun. Rev. 7:8 (Sep 2008), 606–611.
135. Manson, J.J., Ma, A., Rogers, P., Mason, L.J., Berden, J.H., van der Vlag, J., D'Cruz, D.P., Isenberg, D.A., Rahman, A., Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res. Ther., 11(5), Oct 14 2009, R154.
136. Tsirogianni, A., Pipi, E., Soufleros, K., Relevance of anti-C1q autoantibodies to lupus nephritis. Ann. N. Y. Acad. Sci. 1173 (Sep 2009), 243–251.
137. Jesus, A.A., Silva, C.A., Carneiro-Sampaio, M., Sheinberg, M., Mangueira, C.L., Marie, S.K., Liphaus, B.L., Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1173 (Sep 2009), 235–238.
138. Moroni, G., Radice, A., Giammarresi, G., Quaglini, S., Gallelli, B., Leoni, A., Li Vecchi, M., Messa, P., Sinico, R.A., Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann. Rheum. Dis. 68:2 (Feb 2009), 234–237.
139. Renaudineau, Y., Deocharan, B., Jousse, S., Renaudineau, E., Putterman, C., Youinou, P., Anti-alpha-actinin antibodies: a new marker of lupus nephritis. Autoimmun. Rev. 6:7 (Aug 2007), 464–468.
140. Renaudineau, Y., Croquefer, S., Jousse, S., Renaudineau, E., Devauchelle, V., Guéguen, P., Hanrotel, C., Gilburd, B., Saraux, A., Shoenfeld, Y., Putterman, C., Youinou, P., Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum. 54:8 (Aug 2006), 2523–2532.
141. Becker-Merok, A., Kalaaji, M., Haugbro, K., Nikolaisen, C., Nilsen, K., Rekvig, O.P., Nossent, J.C., Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Res. Ther., 8(6), 2006, R162.
142. Hoftman, A.D., Tai, L.Q., Tze, S., Seligson, D., Gatti, R.A., McCurdy, D.K., MAGE-B2 autoantibody: a new biomarker for pediatric systemic lupus erythematosus. J. Rheumatol. 35:12 (Dec 2008), 2430–2438.
143. Meyer, O., Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine 77:5 (Oct 2010), 384–389.
144. Tan, Y., Yu, F., Yang, H., Chen, M., Fang, Q., Zhao, M.H., Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum. Immunol. 69:12 (Dec 2008), 840–844.
145. Bauer, J.W., Baechler, E.C., Petri, M., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med., 3, 2006, e491.
146. Fu, Q., Chen, X., Cui, H., et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res. Ther., 10, 2008, R112.
147. Kulkarni, O., Anders, H.J., Chemokines in lupus nephritis. Front. Biosci. 13 (May 1 2008), 3312–3320.
148. Abdel Galil, S.M., Ezzeldin, N., El-Boshy, M.E., The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine 76:2 (Dec 2015), 280–287.
149. Chun, H.Y., Chung, J.W., Kim, H.A., Yun, J.M., Jeon, J.Y., Ye, Y.M., Kim, S.H., Park, H.S., Suh, C.H., Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27:5 (Sep 2007), 461–466.
150. Neusser, M.A., Lindenmeyer, M.T., Edenhofer, I., et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod. Pathol. 24 (2011), 98–107.
151. Sabry, A., Sheashaa, H., El-Husseini, A., El-Dahshan, K., Abdel-Rahim, M., Elbasyouni, S.R., Intercellular adhesion molecules in systemic lupus erythematosus patients with lupus nephritis. Clin. Rheumatol. 26:11 (Nov 2007), 1819–1823.
152. Yao, G.H., Liu, Z.H., Zhang, X., Zheng, C.X., Chen, H.P., Zeng, C.H., Li, L.S., Circulating thrombomodulin and vascular cell adhesion molecule-1 and renal vascular lesion in patients with lupus nephritis. Lupus 17:8 (Aug 2008), 720–726.
153. Skeoch, S., Haque, S., Pemberton, P., Bruce, I.N., Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. Lupus 23:8 (Jul 2014), 819–824.
154. Wu, T., Ding, H., Han, J., Arriens, C., Wei, C., Han, W., Pedroza, C., Jiang, S., Anolik, J., Petri, M., Sanz, I., Saxena, R., Mohan, C., Antibody-array-based proteomic screening of serum markers in systemic lupus erythematosus: a discovery study. J. Proteome Res., 7, Jun 2016.
155. Mok, C.C., Ding, H.H., Kharboutli, M., Mohan, C., Axl, Ferritin, IGFBP2 and TNFR2 as biomarkers in systemic lupus erythematosus. Arthritis Care Res., Jan 8 2016.
156. Ding, H., Kharboutli, M., Saxena, R., Wu, T., Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. Clin. Exp. Immunol. 184:1 (Apr 2016), 11–18.
157. Wu, T., Xie, C., Han, J., Ye, Y., Singh, S., Zhou, J., Li, Y., Ding, H., Li, Q.Z., Zhou, X., Putterman, C., Saxena, R., Mohan, C., Insulin-like growth factor binding protein-4 as a marker of chronic lupus nephritis. PLoS One, 11(3), Mar 28 2016, e0151491.
158. Parodis, I., Ding, H., Zickert, A., Mohan, C., Gunnarsson, I., Serum ferritin and insulin-like growth factor-binding protein 2 as biomarkers of clinical and histopathological treatment response in lupus nephritis [abstract]. Arthritis Rheum., 67(Suppl. 10), 2015.
159. Parodis, I., Ding, H., Zickert, A., Mohan, C., Gunnarsson, I., Serum Axl and tumor necrosis factor receptor II portend long-term renal outcome in lupus nephritis [abstract]. Arthritis Rheum., 67(Suppl. 10), 2015.
160. Hutcheson, J., Ye, Y., Han, J., Arriens, C., Saxena, R., Li, Q.Z., Mohan, C., Wu, T., Resistin as a potential marker of renal disease in lupus nephritis. Clin. Exp. Immunol. 179:3 (Mar 2015), 435–443.
161. De Sanctis, J.B., Zabaleta, M., Bianco, N.E., Garmendia, J.V., Rivas, L., Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 42:4 (May 2009), 272–274.
162. Chung, C.P., Long, A.G., Solus, J.F., Rho, Y.H., Oeser, A., Raggi, P., Stein, C.M., Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 18:9 (Aug 2009), 799–806.
163. Rastin, M., Soltani, S., Nazemian, F., Sahebari, M., Mirfeizi, S.Z., Tabasi, N., Mahmoudi, M., Expression of T helper 17 and regulatory T cell cytokines and molecules in glomerulonephritis class IV systemic lupus erythematosus. Iran J. Kidney Dis. 10:3 (May 2016), 113–118.
164. López, P., Rodríguez-Carrio, J., Caminal-Montero, L., Mozo, L., Suárez, A., A pathogenic IFNα, BLyS and IL-17 axis in systemic lupus erythematosus patients. Sci. Rep., 6, Feb 5 2016, 20651.
165. Peliçari Kde, O., Postal, M., Sinicato, N.A., Peres, F.A., Fernandes, P.T., Marini, R., Costallat, L.T., Appenzeller, S., Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus. Clin. (Sao Paulo) 70:5 (May 2015), 313–317.
166. Zickert, A., Amoudruz, P., Sundström, Y., Rönnelid, J., Malmström, V., Gunnarsson, I., IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol., 16, Feb 12 2015, 7.
167. Elia, G., Interferon-γ-inducible chemokines in systemic lupus erythematosus. Clin. Ter. 166:1 (2015), e41–e46.
168. Schiffer, L., Worthmann, K., Haller, H., Schiffer, M., CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?. Clin. Exp. Immunol. 179:1 (Jan 2015), 85–89.
169. Marie, M.A., Abu Khalil, R.E., Habib, H.M., Urinary CXCL10: a marker of nephritis in lupus patients. Reumatismo. 65:6 (Mar 17 2014), 292–297.
170. Wu, C., Yang, M., Zhou, Z., Feng, X., Zhong, X., Cui, S., Wu, L., [Urinary soluble intercellular adhesion molecule-1 and vascular cellular adhesion molecule-1: potential biomarkers of active lupus nephritis]. Nan Fang Yi Ke Da Xue Xue Bao 35:9 (Aug 2015), 1272–1276 1282. Chinese.
171. Howe, H.S., Kong, K.O., Thong, B.Y., Law, W.G., Chia, F.L., Lian, T.Y., Lau, T.C., Chng, H.H., Leung, B.P., Urine sVCAM-1 and sICAM-1 levels are elevated in lupus nephritis. Int. J. Rheum. Dis. 15:1 (Feb 2012), 13–16.
172. Abd-Elkareem, M.I., Al Tamimy, H.M., Khamis, O.A., Abdellatif, S.S., Hussein, M.R., Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin. Exp. Nephrol. 14:6 (Dec 2010), 548–557.
173. Dong, G., Ye, R., Shi, W., Liu, S., Wang, T., Yang, X., Yang, N., Yu, X., IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin. Med. J. 116:4 (Apr 2003), 543–548.
174. Apostolidis, S.A., Crispín, J.C., Tsokos, G.C., IL-17-producing T cells in lupus nephritis. Lupus 20:2 (Feb 2011), 120–124.
175. Chen, D.Y., Chen, Y.M., Wen, M.C., Hsieh, T.Y., Hung, W.T., Lan, J.L., The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 21:13 (Nov 2012), 1385–1396.
176. Crispín, J.C., Oukka, M., Bayliss, G., Cohen, R.A., Van Beek, C.A., Stillman, I.E., Kyttaris, V.C., Juang, Y.T., Tsokos, G.C., Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181:12 (Dec 15 2008), 8761–8766.
177. Mok, M.Y., Wu, H.J., Lo, Y., Lau, C.S., The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J. Rheumatol. 37:10 (Oct 2010), 2046–2052.
178. Wolf, B.J., Spainhour, J.C., JM, A., MG, J., Petri, M., JC, O., Development of biomarker models to predict outcomes in lupus nephritis. Arthritis Rheum., Feb 11 2016.
179. Brunner, H.I., Bennett, M.R., Abulaban, K., Klein-Gitelman, M.S., O'Neil, K.M., Tucker, L., Ardoin, S.P., Rouster-Stevens, K.A., Onel, K.B., Singer, N.G., Anne Eberhard, B., Jung, L.K., Imundo, L., Wright, T.B., Witte, D., Rovin, B.H., Ying, J., Devarajan, P., Development of a novel renal activity index of lupus nephritis in children and young adults. Arthritis Care Res. 68:7 (Jul 2016), 1003–1011.
180. Varghese, S.A., Powell, T.B., Budisavljevic, M.N., Oates, J.C., Raymond, J.R., Almeida, J.S., Arthur, J.M., Urine biomarkers predict the cause of glomerular disease. J. Am. Soc. Nephrol. 18:3 (Mar 2007), 913–922 Epub 2007 Feb 14.
181. Niwa, T., Biomarker discovery for kidney diseases by mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 870:2 (Jul 15 2008), 148–153.
182. Santucci, L., Candiano, G., Bruschi, M., Bodria, M., Murtas, C., Petretto, A., Ghiggeri, G.M., Urinary proteome in a snapshot: normal urine and glomerulonephritis. J. Nephrol. 26:4 (Jul-Aug 2013), 610–616.
183. Pejcic, M., Stojnev, S., Stefanovic, V., Urinary proteomics–a tool for biomarker discovery. Ren. Fail. 32:2 (Jan 2010), 259–268.
184. Wu, T., Fu, Y., Brekken, D., Yan, M., Zhou, X.J., Vanarsa, K., Deljavan, N., Ahn, C., Putterman, C., Mohan, C., Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis. J. Immunol. 184:4 (Feb 15 2010), 2183–2193.
185. Zhang, X., Jin, M., Wu, H., Nadasdy, T., Nadasdy, G., Harris, N., Green-Church, K., Nagaraja, H., Birmingham, D.J., Yu, C.Y., Hebert, L.A., Rovin, B.H., Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 74:6 (Sep 2008), 799–807.
186. Mosley, K., Tam, F.W., Edwards, R.J., Crozier, J., Pusey, C.D., Lightstone, L., Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 45:12 (Dec 2006), 1497–1504.
187. Thongboonkerd, V., Biomarker discovery in glomerular diseases using urinary proteomics. Proteomics Clin. Appl. 2:10 − 11 (Oct 2008), 1413–1421.
188. Vaidyanathan, K., Urinary proteomics and metabolomics in the diagnosis of pediatric disorders. Proteomics Clin. Appl. 9:5–6 (Jun 2015), 482–489.
189. Mahler, M., Fritzler, M.J., Anti-dsDNA antibody testing in the clinic: Farr or ELISA?. Nat. Clin. Pract. Rheumatol. 3:2 (Feb 2007), 72–73.
190. Ghirardello, A., Villalta, D., Morozzi, G., Afeltra, A., Galeazzi, M., Gerli, R., Mathieu, A., Meroni, P.L., Migliorini, P., Radice, A., Riccieri, V., Ruffatti, A., Sebastiani, G.D., Tincani, A., Doria, A., FIRMA group, Evaluation of current methods for the measurement of serum anti double-stranded DNA antibodies. Ann. N. Y. Acad. Sci. 1109 (Aug 2007), 401–406.
191. Birmingham, D., Irshaid, F., Nagaraja, H., Zou, X., Tsao, B., Wu, H., Rovin, B., The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 19:11 (2010), 1272–1280.